search
Back to results

Aging Stereotypes and Prodromal Alzheimer's Disease (AGING)

Primary Purpose

Mild Cognitive Impairment (MCI)

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Diagnosis of MCI versus No MCI (SCI or healthy patient)
Diagnosis of MCI versus No MCI (SCI or healthy patient)
Sponsored by
Assistance Publique Hopitaux De Marseille
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Mild Cognitive Impairment (MCI)

Eligibility Criteria

50 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must be at least 50 years old
  • Patients must report memory complaints
  • Patients must show signs of MCI (amnestic single or multiple domain) on the following short cognitive tests

Exclusion Criteria:

  • Probable Alzheimer's Disease according to NINCDS-ADRDA criteria (MA patients will be excluded from the study because false-positive errors only concern MCI status, not AD)
  • Psychiatric disorders (schizophrenia, bipolar disorder)
  • Cranial trauma
  • Developmental pathologies
  • Depression (score greater than or equal to 10 on GDS)
  • Psychotropic medication if modified in the last 3 months

Sites / Locations

  • Assistance Publique Hôpitaux de MarseilleRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Standard instruction

Reduced threat instruction

Arm Description

Outcomes

Primary Outcome Measures

Neuropsychological tests
Neuropsychological battery used for the diagnosis of Mild Cognitive Impairment (MCI, amnestic single or multiple domain)

Secondary Outcome Measures

Neuroimaging biomarkers of neurodegeneration
Structural MRI (Hippocamp) and Florbetapir© PET (β-amyloid deposition)
Physiological stress
cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).
Self-report questionnaires
Vulnerability factors for stereotyping threat effects are assessed
Heart rate variability (thin elasticized heart rate transmitter belt),
Physiological stress
Skin conductance (wristwatch)
Physiological stress
Salivary biomarkers
cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).

Full Information

First Posted
April 10, 2017
Last Updated
July 23, 2018
Sponsor
Assistance Publique Hopitaux De Marseille
search

1. Study Identification

Unique Protocol Identification Number
NCT03138018
Brief Title
Aging Stereotypes and Prodromal Alzheimer's Disease
Acronym
AGING
Official Title
The Potential Impact of Aging Stereotypes in the Assessment of Memory Deficits and Screening for Prodromal State of Alzheimer's Disease
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 6, 2018 (Actual)
Primary Completion Date
July 1, 2023 (Anticipated)
Study Completion Date
July 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Because of the lengthening of life expectancy, more and more people are concerned with the effects of aging on their mental faculties (e.g., memory decline) and with the possibility of getting Alzheimer's Disease (AD) or other forms of dementia. This increasing awareness of AD has already resulted in a growing demand for neuropsychological testing. AD's research also emphasizes the need for early screening to improve the prediction of the disease progression and the efficacy of any future therapy. Such a drive to screen for pre-dementia raises the challenging issue of frontline identification of individuals in the preclinical or early clinical stages of AD. Mild Cognitive Impairment (MCI) is typically considered to be the prodromal state of AD, and is therefore at the core of the drive for early screening. Moreover, Pre-MCI so called SCI (Subjective Cognitive Impairment) can precede AD for 15 years. However, many individuals diagnosed with MCI do not convert to AD, some remaining stable and others even reversing back to normal (with rates of reversion to normal varying from 4.5% to as high as 53%). This over-diagnosis bias, which has been largely overlooked, is at the core of the present project at the interface of human and life sciences. Here, we argue that an important source of overdiagnosis in the prodromal state of AD comes from negative aging stereotypes (e.g., the culturally shared beliefs that aging inescapably causes severe cognitive decline and diseases such as AD) that permeate neuropsychological screening. There is ample evidence in the laboratory that such stereotypes contribute to the differences observed in the healthy population between younger and older adults in explicit memory tasks. Additionally, three pilot (lab) studies specifically conducted for the present ANR project showed that the threat of being judged stereotypically undermines the controlled use of memory of healthy older adults and simultaneously intensifies their automatic response tendencies, resulting in impaired memory performance. The present proposal goes several steps further by examining for the first time whether aging stereotypes are powerful enough to implicitly permeate the clinical neuropsychological testing and thus inflate memory deficits in older adults judged "at risk" (based on either epidemiological criteria or memory complaints), resulting in false-positive detection of SCI and MCI. This provocative hypothesis will be tested while 1) using biomarkers of neurodegeneration to distinguish false-positives from true MCI, and 2) using biomarkers of stress to examine whether and how aging stereotypes can lead to acute physiological stress during neuropsychological testing. This innovative project has the potential to offer new recommendations to improve the diagnosis accuracy of prodromal state of AD, with positive consequences for older people's wellbeing.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Cognitive Impairment (MCI)

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
260 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard instruction
Arm Type
Active Comparator
Arm Title
Reduced threat instruction
Arm Type
Experimental
Intervention Type
Diagnostic Test
Intervention Name(s)
Diagnosis of MCI versus No MCI (SCI or healthy patient)
Intervention Description
Neuropsychological tests
Intervention Type
Diagnostic Test
Intervention Name(s)
Diagnosis of MCI versus No MCI (SCI or healthy patient)
Intervention Description
Neuroimaging biomarkers of neurodegeneration
Primary Outcome Measure Information:
Title
Neuropsychological tests
Description
Neuropsychological battery used for the diagnosis of Mild Cognitive Impairment (MCI, amnestic single or multiple domain)
Time Frame
48 months
Secondary Outcome Measure Information:
Title
Neuroimaging biomarkers of neurodegeneration
Description
Structural MRI (Hippocamp) and Florbetapir© PET (β-amyloid deposition)
Time Frame
48 months
Title
Physiological stress
Description
cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).
Time Frame
48 months
Title
Self-report questionnaires
Description
Vulnerability factors for stereotyping threat effects are assessed
Time Frame
48 months
Title
Heart rate variability (thin elasticized heart rate transmitter belt),
Description
Physiological stress
Time Frame
48 months
Title
Skin conductance (wristwatch)
Description
Physiological stress
Time Frame
48 months
Title
Salivary biomarkers
Description
cortisol, dehydroepiandrosterone (DHEA) and its sulfated stable form (DHEAS) from the HPA axis, and Immunoglobulin A (IgA).
Time Frame
48 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must be at least 50 years old Patients must report memory complaints Patients must show signs of MCI (amnestic single or multiple domain) on the following short cognitive tests Exclusion Criteria: Probable Alzheimer's Disease according to NINCDS-ADRDA criteria (MA patients will be excluded from the study because false-positive errors only concern MCI status, not AD) Psychiatric disorders (schizophrenia, bipolar disorder) Cranial trauma Developmental pathologies Depression (score greater than or equal to 10 on GDS) Psychotropic medication if modified in the last 3 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bernard MICHEL, PH
Phone
491744675
Ext
+33
Email
bmichel@ap-hm.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Isabelle REGNER, PhD
Phone
413550993
Ext
+33
Email
isabelle.regner@univ-amu.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Urielle DESALBRES, Director
Organizational Affiliation
ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Hôpitaux de Marseille
City
Marseille
ZIP/Postal Code
13354
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bernard MICHEL, PH
Phone
491744675
Ext
+33
Email
bmichel@ap-hm.fr
First Name & Middle Initial & Last Name & Degree
Bernard MICHEL, PH

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31594904
Citation
Gauthier K, Morand A, Dutheil F, Alescio-Lautier B, Boucraut J, Clarys D, Eustache F, Girard N, Guedj E, Mazerolle M, Paccalin M, de la Sayette V, Zarea A, Huguet P, Michel BF, Desgranges B; AGING consortium; Regner I. Ageing stereotypes and prodromal Alzheimer's disease (AGING): study protocol for an ongoing randomised clinical study. BMJ Open. 2019 Oct 7;9(10):e032265. doi: 10.1136/bmjopen-2019-032265.
Results Reference
derived

Learn more about this trial

Aging Stereotypes and Prodromal Alzheimer's Disease

We'll reach out to this number within 24 hrs